(Q39448675)

English

Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

1 reference

based on heuristic

inferred from title

Erb-b2 receptor tyrosine kinase 2

1 reference

based on heuristic

inferred from title

author name string

Naomi Ono

1

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Toshikazu Yamazaki

2

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Yoshito Nakanishi

3

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Toshihiko Fujii

4

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Kiyoaki Sakata

5

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Yukako Tachibana

6

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Atsushi Suda

7

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Kihito Hada

8

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Takaaki Miura

9

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Shigeo Sato

10

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Ryoichi Saitoh

11

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Kohnosuke Nakano

12

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Takuo Tsukuda

13

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Toshiyuki Mio

14

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Nobuya Ishii

15

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Osamu Kondoh

16

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Yuko Aoki

17

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

publication date

13 December 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

103

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

342-349

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

HSP90 and the chaperoning of cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02144.X

21 January 2018

Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02144.X

21 January 2018

V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02144.X

21 January 2018

Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02144.X

21 January 2018

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02144.X

21 January 2018

High HSP90 expression is associated with decreased survival in breast cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02144.X

21 January 2018

Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02144.X

21 January 2018

Heat shock protein 90 as a drug target: some like it hot.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02144.X

21 January 2018

Heat shock protein 90 as a molecular target for cancer therapeutics

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02144.X

21 January 2018

Targeting the dynamic HSP90 complex in cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02144.X

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02144.X

21 January 2018

Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02144.X

21 January 2018

A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02144.X

21 January 2018

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02144.X

21 January 2018

Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02144.X

21 January 2018

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02144.X

21 January 2018

Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02144.X

21 January 2018

Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02144.X

21 January 2018

A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02144.X

21 January 2018

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02144.X

21 January 2018

Targeting Hsp90: small-molecule inhibitors and their clinical development

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02144.X

21 January 2018

Update on Hsp90 inhibitors in clinical trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02144.X

21 January 2018

Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02144.X

21 January 2018

Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02144.X

21 January 2018

The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02144.X

21 January 2018

Resiliency and vulnerability in the HER2-HER3 tumorigenic driver

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02144.X

21 January 2018

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02144.X

21 January 2018

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2011.02144.X

21 January 2018

Identifiers

10.1111/J.1349-7006.2011.02144.X

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39448675&oldid=1828766863"